Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.